Public Meetings, Workshops, and Webinars
FDA’s Office of Women’s Health (OWH) is pleased to present a series of educational webinars on a broad range of topics to promote, protect, and advance the health of women. These webinars target the needs of researchers, healthcare professionals, and students.
Continuing education (CE) credit is available for some of our live and home study webinars. If you are a physician, nurse, nurse practitioner, or pharmacist, please refer to the individual webinar listing for complete CE information.
Past Public Meetings, Workshops, and Webinars
On May 11th, 2022, the FDA Office of Women’s Health hosted a webinar in collaboration with CDER’s Division of Pediatrics and Maternal Health to discuss FDA’s current pregnancy and lactation labeling system [also known as the Pregnancy and Lactation Labeling Rule (PLLR)], which replaced a previous approach that used letter categories. This webinar will help learners examine how prescription drug labeling can be used to inform prescribing for pregnant and lactating individuals.
On May 9th, 2022, FDA’s Office of Women’s Health and the Johns Hopkins Center of Excellence in Regulatory Science and Innovation held a virtual public workshop to discuss the role of real-world data (RWD) to understand medication use in pregnancy and lactation. Panels discussed ways to address knowledge gaps, opportunities, and challenges of collecting RWD, and current regulatory perspectives on the collection and potential use of RWD.
This 6-module online, self-paced course was developed in partnership with the National Institutes of Health (NIH’s) Office of Research on Women’s Health (ORWH). The course is aimed at clinicians and researchers looking to learn about sex- and gender-related differences in key disease areas including: Immunology, Cardiovascular Disease, Pulmonary Disease, Neurology, Endocrinology, and Mental Health.
On November 19, 2020, the FDA Office of Women’s Health hosted a public meeting to highlight scientific evidence and knowledge gaps about sex and gender differences in cannabidiol (CBD) use and responses. Panel topics included: Perspectives from Patients and Healthcare Professionals, Sex Differences in the Effects of Cannabinoids, Use of CBD and Other Cannabinoids in Pregnancy, and Government Agency Perspectives on CBD Research and Evaluation.
On September 27th and 28th, 2018, the FDA Office of Women’s Health together with FDA’s Center for Drug Evaluation and Research and Center for Tobacco Products, hosted a 2-day public meeting to discuss sex and gender differences in prescription opioid use and pain neurobiology. The meeting brought together 40 nationally and internationally recognized clinicians and scientists to highlight evidence and share insights on sex and gender differences related to opioid and nicotine use, abuse, and recovery.